麻豆视频

Market Trends and Insights

Rising Prevalence of Drug-Resistant TB Strains

Multidrug-resistant tuberculosis cases climbed to an estimated 410,000 globally in 2025, with rifampicin-resistant strains accounting for 3.6% of new cases and 18% of previously treated cases, according to WHO surveillance data. This epidemiological shift is forcing national programs to pivot from empirical treatment to genotypic drug-susceptibility testing, which requires molecular assays capable of detecting mutations in rpoB, katG, and inhA genes within 2 hours. This technical bar only cartridge-based NAAT platforms currently meet at scale. Germany鈥檚 5.7% multidrug-resistant incidence and C么te d鈥橧voire鈥檚 22% rifampicin resistance among retreatment cases show how resistance patterns differ by geography. Xpert MTB/XDR delivers actionable drug profiles in 90 minutes, while Abbott鈥檚 RealTime MTB RIF/INH assay achieves 94.8% sensitivity for rifampicin and 88.3% for isoniazid, letting clinicians tailor therapy promptly. Nations are also piloting targeted next-generation sequencing to comprehensively map resistance, moving diagnostic workflows from culture-dependent to molecular-first approaches.

WHO Endorsement & National Roll-Outs of NAAT Platforms

WHO鈥檚 March 2024 guideline update placed molecular rapid tests at the front of all diagnostic algorithms and introduced targeted sequencing advice for drug-resistant surveillance WHO.^{[3]World Health Organization, 鈥淕lobal Tuberculosis Report 2025,鈥� WHO.INT} India鈥檚 Initiative for Promoting Affordable and Quality TB Tests boosted Xpert uptake tenfold and cut prices by up to 50%, scaling from 56 to 211 labs in five years. Uganda: by decentralizing NAATs to district hospitals, shortened the median time to treatment initiation and increased same-day confirmations, NEJM. WHO prequalification is the de facto gatekeeper for Global Fund, USAID, and UNITAID financing; Cepheid鈥檚 Ultra assay and Eiken鈥檚 TB-LAMP together triggered USD 340 million of commitments in 1Q 2025. India鈥檚 NTEP scaled molecular capacity nationwide, while the Philippines achieved a 1,008% surge in case detection during a Truenat pilot on the Bantayan Islands, where battery-powered devices bypass erratic grid supply. The policy cascade shortens technology diffusion cycles to fewer than 24 months across Asia-Pacific, a timeline once witnessed only in high-income markets.

Emergence of AI-Powered Microscopy & Digital Radiology

A 12-country study revealed that computer-vision algorithms achieved 89% sensitivity and 97% specificity on Ziehl-Neelsen smears for USD 0.30 per test, compared to USD 10 for NAAT cartridges.^{[4]Nature Medicine, 鈥淎I-Enhanced Microscopy for Tuberculosis Detection: A 12-Country Validation Study,鈥� NATURE.COM} Ministries are now implementing AI microscopy as a triage layer, with flagged positive cases proceeding to confirmatory NAAT testing and negative cases exiting the process. This strategy has reduced overall molecular testing volume by 40% without compromising diagnostic yield. In 2025, Delft Imaging processed 2.3 million chest X-rays, identifying 87,000 presumptive cases that would have been missed through symptom-based screening. However, the algorithm's sensitivity drops to 72% among HIV-coinfected patients, leading to delays in regulatory approvals in South Africa and Kenya.

Decentralized Near-POC Molecular Platforms

In 2025, Molbio's Truenat, a battery-operated PCR system, secured 3,400 orders across Nigeria, Kenya, and Papua New Guinea, effectively eliminating the USD 1.20 cold-chain surcharge in rural clinics. Cepheid's Omni prototype optimized the user process by reducing steps from seven to two, resulting in a 60% decrease in error rates during trials conducted in Indonesia and Mozambique. A study published in PLOS Medicine reported an incremental cost-effectiveness of USD 280 per DALY averted when devices are located within 10 kilometers of communities, a figure well below WHO's established thresholds.

High Cost of Molecular Tests & Cartridges

Traditional desktop platforms can exceed USD 19,000, whereas Tulane鈥檚 lab-in-tube device costs under USD 800 and keeps per-test pricing below USD 3. Economic analyses in Brazil and India showed Diaskintest at USD 22.6 and USD 41.0 per correct case, while TSPOT.TB delivered greater effectiveness at incremental costs of USD 55-74. Cepheid鈥檚 cost-price cartridge offer narrows the gap, yet a sustainable reimbursement model remains critical for widespread adoption.

Shortage of Skilled Laboratory Infrastructure

A proficiency survey in Ethiopia revealed only 81.92% competency in smear microscopy, with performance tied to refresher training and years of experience. Sub-Saharan facilities reported 66% Xpert coverage but just 4% Line Probe Assay uptake owing to funding and workforce limitations, BMJ Global Health. WHO鈥檚 laboratory manual emphasizes quality-assured capacity building, while the CDC鈥檚 Tuberculosis Education and Training Network and the Curry International Tuberculosis Center provide ongoing webinars and hands-on coaching. Nigeria鈥檚 public-private model showed that training, along with instrument redistribution, produced a 28-fold increase in suspected referrals.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Tuberculosis Diagnostics Market Segment Analysis

In 2025, culture-based assays accounted for 38.45% of the revenue, with projections indicating a 6.54% annual growth rate. This increase is driven by WHO guidelines requiring phenotypic confirmation for all rifampicin-resistant cases. While NAAT remains the leading method for primary screening, laboratories are increasingly integrating rapid genotyping with subsequent culture testing. This dual-track workflow enables quick therapy initiation through molecular methods, while culture testing provides detailed insights to optimize treatment regimens.

Continued donor funding sustains the cost-effectiveness of smear microscopy at USD 2 per slide, particularly in regions conducting high volumes of Ziehl-Neelsen tests, such as India. However, as digital microscopy and AI algorithms achieve sensitivity levels comparable to NAAT at significantly lower reagent costs, traditional smear microscopy is gradually being relegated to peripheral triage applications.

In 2025, molecular diagnostics accounted for 45.23% of revenue. However, AI-enhanced microscopy is witnessing the fastest growth rate among modalities, increasing at 7.15% annually. This growth is driven by the adoption of computer-vision software that repurposes existing optical systems. Additionally, immunoassays, particularly interferon-gamma release assays (IGRAs), play a critical role in screening latent infections within immigration and transplant groups across Europe and North America. This niche market is expected to grow at an annual rate of 4.2%, supported by stricter occupational mandates.

Culture technology remains indispensable for resistance phenotyping. When integrated with automated MGIT systems, automation has reduced turnaround times from 42 days to as few as 14 days. Consequently, the tuberculosis diagnostics industry is transitioning toward integrated algorithms that utilize AI microscopy for triage, confirm diagnoses with NAAT, and finalize therapy plans using culture profiles.

In 2025, diagnostic laboratories accounted for 59.20% of the revenue. However, hospitals and clinics are projected to grow at a CAGR of 6.67% through 2031. This growth is driven by benchtop NAAT modules that reduce turnaround times to under two hours. Additionally, subscription models that bundle instruments, maintenance, and software into per-test fees are lowering upfront spending barriers. This approach is enabling smaller secondary hospitals to enter the tuberculosis diagnostics market.

Although academic centers and research institutes contribute less than 5% of sales, they are at the forefront of developing host-response transcriptomic tests that could advance diagnosis beyond traditional sputum methods. In 2025, a study demonstrated 83% sensitivity for a whole-blood gene-signature assay tested on 2,400 patients. This development highlights a pathway for non-sputum detection at the community level.

Geography Analysis

The Americas, EMEA and APAC Tuberculosis Diagnostics Market

North America accounted for 39.10% of the tuberculosis diagnostics market in 2025, aided by comprehensive insurance coverage and consistent CDC laboratory upgrades. Asia-Pacific is forecast to expand at a 6.75% CAGR, driven by India鈥檚 one-third share of the global burden and policy shifts from smear microscopy to NAAT. Europe posted 38,993 cases across 29 EU/EEA nations in 2024; Ukrainian refugee screening recorded 12.8 per 100,000 incidence with 26% multidrug resistance, prompting intensified entry screening. South America benefits from national Xpert scale-up; Brazil鈥檚 rollout increased notifications by 9.7% and catalyzed multisector coordination. The Middle East and Africa see uneven progress: while Nigeria鈥檚 AI-linked vans record 1.75 times higher positivity in hotspots, only 4% of labs can run Line Probe Assays. Diaskintest is cheaper than tuberculin in Brazil and India, but TSPOT.TB delivers higher accuracy at added expense, underscoring divergent procurement choices

Regulatory Landscape

Tuberculosis diagnostics are shaped by a combination of WHO policy guidance and country-level medical device regulation. WHO updated Module 3 guidance on TB diagnosis in 2024-2025, reinforcing rapid molecular testing within diagnostic algorithms and adding recommendations on sequencing for drug-resistance surveillance, which then feeds into national test menus and tender specifications in high-burden settings financed by the Global Fund, USAID, and UNITAID.

In the United States, the FDA continues to act as a key gatekeeper for both latent TB infection tests and laboratory automation workflows. This is reflected in Revvity's April 2025 FDA clearance for the Auto-Pure 2400 integrated with the T-SPOT.TB test, as well as the FDA's March 2026 proposed reclassification of Mycobacterium tuberculosis cell-mediated immunity tests. In Europe, the EU IVD Regulation (IVDR, Regulation 2017/746) places TB IVDs in Class C, which increases reliance on Notified Bodies for conformity assessment and tightens expectations around quality systems and clinical evidence for manufacturers commercializing molecular, immunoassay, and AI-enabled diagnostic solutions.

Market Opportunities and Future Outlook

Decentralized testing remains a key whitespace, with programs pushing near point-of-care deployment and alternative specimen pathways. In March 2026, WHO recommended new near point-of-care TB diagnostic tools with under-one-hour turnaround. In May 2026, WHO and the Stop TB Partnership published a toolkit focused on near point-of-care and swab-based testing, which provides implementation support for shifting testing closer to community settings and reducing dependence on centralized laboratories.

Financing and implementation infrastructure also shape how much scale-up translates into higher case detection, particularly where connectivity and workflow integration affect utilization. Unitaid has highlighted an active USD 44 million investment portfolio (since 2022) aimed at improving access to TB diagnosis and reducing costs. Its May 2025 USD 15.3 million investment for drug-resistant TB testing and treatment across 16 countries, with KELIN, Partners in Health, and the Stop TB Partnership, further points to demand creation and system-strengthening alongside product procurement. Stop TB Partnership programs such as the Introducing New Tools Project broaden the adoption runway for integrated solutions that bundle ultra-portable digital X-ray, AI computer-aided detection, and targeted sequencing with deployment support.